Long-Term Efficacy of Tirzepatide in Managing Heart Failure
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 24th, 2025
|
Obesity increases both the risk and severity of heart failure, as adipocytes contribute to a proinflammatory environment that can further damage cardiac tissues. Research has shown that reducing epicardial adipocyte volume through weight loss can mitigate heart failure risk and improve symptoms. Tirzepatide, a widely used antidiabetic medication that aids in weight control, was investigated in an Eli Lilly–funded study for its potential to manage symptoms in individuals with heart failure.
The clinical study enrolled 364 participants, averaging 65 years of age, who had been diagnosed with chronic heart failure according to New York Heart Association criteria. Baseline assessment using the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) produced an average score of 54, where 100 indicates the most severe disease stage. The cohort had a mean body weight of approximately 103 kilograms, and inflammatory status showed a C-reactive protein level of 5.8 mg/L. Participants were randomly assigned to receive a weekly subcutaneous injection of either placebo or 2.5 mg of tirzepatide. Tirzepatide functions by binding to and activating the glucagon-like peptide-1 receptor, thereby reducing hyperglycemia and promoting weight loss.
After a median follow-up period of 104 weeks, the researchers found that tirzepatide use reduced the risk of heart failure exacerbation by 46%. This effect was evidenced by a mean 19.5-point reduction in the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) score at week 52, which was significantly greater than the 12.7-point improvement seen in the placebo group. These clinical gains were further supported by notable weight loss and decreased inflammation, as indicated by lower C-reactive protein levels. The researchers also noted that while tirzepatide use was linked to gastrointestinal discomfort, it occurred at a lower frequency than previously reported.
The clinical study enrolled 364 participants, averaging 65 years of age, who had been diagnosed with chronic heart failure according to New York Heart Association criteria. Baseline assessment using the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) produced an average score of 54, where 100 indicates the most severe disease stage. The cohort had a mean body weight of approximately 103 kilograms, and inflammatory status showed a C-reactive protein level of 5.8 mg/L. Participants were randomly assigned to receive a weekly subcutaneous injection of either placebo or 2.5 mg of tirzepatide. Tirzepatide functions by binding to and activating the glucagon-like peptide-1 receptor, thereby reducing hyperglycemia and promoting weight loss.
After a median follow-up period of 104 weeks, the researchers found that tirzepatide use reduced the risk of heart failure exacerbation by 46%. This effect was evidenced by a mean 19.5-point reduction in the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) score at week 52, which was significantly greater than the 12.7-point improvement seen in the placebo group. These clinical gains were further supported by notable weight loss and decreased inflammation, as indicated by lower C-reactive protein levels. The researchers also noted that while tirzepatide use was linked to gastrointestinal discomfort, it occurred at a lower frequency than previously reported.